Close menu




July 12th, 2022 | 14:09 CEST

Waiting is not an option! BioNTech, MAS Gold, BASF

  • Gold
  • Biotechnology
  • Inflation
Photo credits: pixabay.com

Inflation is rising and rising. In construction, inflation has already reached almost 20%. Even in everyday life, double-digit inflation rates are not far away. At the same time, infection figures are rising, and it is still uncertain whether gas will flow through Nord Stream 1 again in the coming weeks. Given this mixed situation, many investors are asking how they should invest. Because one thing is clear: waiting is not an option - the real return on many asset classes is clearly negative. We take a look at three stocks and check their future prospects.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , MAS Gold Corp. | CA57457A1057 , BASF SE NA O.N. | DE000BASF111

Table of contents:


    BioNTech: Well prepared for the fall

    Whether BioNTech can emerge as the winner of the Corona situation is not yet certain. Since BioNTech has two hot candidates for the upcoming Corona season, the Company is well-positioned. Actually. Experts from the US Food and Drug Administration (FDA), among others, are currently discussing which vaccines should be launched on the market in the fall. The manufacturers offer solutions specifically directed against Omicron or products intended to be effective against both the original type and Omicron. Doses of the first batches of the vaccines are also still in stock. Given the number of possible solutions, experts warn that the logistics surrounding the vaccines could become more complex, and BioNTech's margins could suffer.

    Nevertheless, the chances are good that the vaccine professionals from Mainz will be able to offer exactly what experts are demanding and vaccinators are accepting in the fall. Since the pandemic has shown that a lot can happen and little can be planned, BioNTech could be well-positioned. The stock also looks attractive from a chart perspective. The share is currently fighting its way out of the sideways movement that has lasted since February. However, it remains to be seen whether the breakout will be successful - BioNTech is now an established stock, making big jumps less likely.

    MAS Gold: Is history repeating itself?

    MAS Gold is the opposite of an established value - at least in Europe. The Company is exploring the La Ronge gold belt in Canada's Saskatchewan province. MAS Gold has several promising smaller properties and is developing them in parallel. The plan is to implement a hub-and-spoke model, where a central processing plant reduces costs and creates flexibility. But for these goals to be achieved, the gold in the ground is critical. A few weeks ago, MAS Gold announced drill results from one-third of its winter drill program. Grades ranging from 0.49 g/t to 3.06 g/t came to light. The task of the Company, led by mining legend Jim Engdahl, will now be to further delineate the deposits and get a picture of the high-grade zones.

    MAS Gold's own belief in moving its projects forward is also evidenced by a financing round involving management and company insiders. With the overall market weakening, especially on the financing side, the stock has come under significant pressure despite the recent successful closing of the capital tranche. This "cliffhanger" can be an opportunity for courageous investors: If MAS Gold successfully implements its strategy and the gold market picks up speed in the wake of general uncertainty, current price levels could be promising. The development of inflation and gold during the 1970s could provide guidance. At that time, gold also only got going with a time lag!

    BASF: More fear than hope

    And what about industrial companies? During past crises, investors could always be sure: In the long term, stocks like BASF always get back on track. And today? Today, energy-intensive industries such as chemicals are threatened with collapse. BASF is painstakingly giving itself a sustainable profile, but tens of thousands of precursors from the Ludwigshafen plant still depend on fossil fuels. If contrary to plans, no more gas flows through Nord Stream 1 in two weeks, shares like BASF will likely come under renewed pressure. The Ludwigshafen shares have already fallen by around 16% in the last three months.


    Inflationary pressure and crisis fears are a dangerous mix. One thing is certain: those investors who do nothing will have to accept a loss of purchasing power in any case, and those who invest incorrectly, likewise. One approach could be to focus on companies that suffer little from the energy price shock and may even have a low valuation. One such candidate, albeit a highly speculative one, is MAS Gold. BioNTech also looks interesting at the moment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 11th, 2026 | 07:20 CEST

    Gold, Silver, Defence, AI, or the Nasdaq? SpaceX Heads for the US Indices – Defying Weakness with Lahontan Gold

    • Mining
    • Gold
    • Silver
    • Commodities
    • Investments
    • nasdaq

    A remarkable phenomenon is currently unfolding in the markets: virtually everything is weakening. From gold to silver, from high-tech to low-tech, whether AI or hydrogen—every sector is undergoing a correction. So far, however, the pullback remains modest when measured against the extraordinary gains achieved over the past 14 months following the tariff-driven sell-off triggered by Donald Trump. During that period, the Nasdaq effectively doubled. Traders know that a volatile interim low will now be reached, particularly over the summer, before the markets look forward to 2027 with renewed hope. This period needs to be bridged, and there may also be a need for hedging. Historically, gold has served this role well, often gaining value when other asset classes came under pressure. Yet gold itself has been one of the best-performing asset classes over the past two years, leading to some profit-taking here as well. Whether the S&P 500 can absorb additional heavyweights such as SpaceX, OpenAI, and Databricks following its historic rally remains to be seen. A fast-track inclusion of SpaceX into the S&P indices was reportedly rejected by S&P Dow Jones, while NASDAQ, Russell, and MSCI are set to list it within a few trading days. This should be exciting! Where are the tangible opportunities for investors?

    Read

    Commented by Tarik Dede on June 11th, 2026 | 07:05 CEST

    Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight

    • Pharma
    • Biotech
    • Biotechnology
    • Cancer

    Cancer remains one of humanity's greatest scourges, and at the same time, it is by far the largest healthcare market of all. But the old-school pharmaceutical giants are running out of oncology pipeline candidates, and now smaller, far more innovative players are increasingly being acquired. The M&A market is currently experiencing extremely dynamic times. This week, for example, GSK announced the acquisition of Nuvalent for USD 10.6 billion in cash. Gilead Sciences, in turn, struck a deal in April with the German company Tubulis—for a total of USD 5 billion. Shortly thereafter, Eli Lilly offered up to USD 7 billion for Kelonia Therapeutics, just to name a few of this year's deals. That is why we are taking a look at the opportunities in the sector today and putting the stocks of Eli Lilly, Vidac Pharma, and GSK under the microscope!

    Read

    Commented by Armin Schulz on June 11th, 2026 | 06:45 CEST

    With Novo Nordisk, MustGrow Biologics, and Bayer: Positioning for Two Megatrends of the Decade

    • biologicals
    • mustard
    • agritech
    • Biotechnology
    • Biotech

    Created and published on behalf of MustGrow Biologics Corp.

    Two seemingly opposing crises—obesity and food scarcity—are creating major investment opportunities this year. While the obesity epidemic is placing increasing strain on healthcare systems, climate shocks and geopolitical conflicts are threatening global agricultural yields. The biotech sector is addressing both challenges through biological compounds for weight management and crop protection. Demand for effective obesity treatments and sustainable agricultural solutions is rising rapidly. Investors who position themselves early in the beneficiaries of this dual transformation may benefit from above-average returns. This is precisely where the three companies we are taking a closer look at today are positioned: Novo Nordisk, MustGrow Biologics, and Bayer.

    Read